Delineation of MGMT promoter hypermethylation as a predictive biomarker for the A071102 clinical trial of veliparib combined with temozolomide (TMZ) using patient-derived xenograft (PDX) GBM models

Category Primary study
JournalJournal of Clinical Oncology
Year 2015
This article has no abstract
Epistemonikos ID: 32980fd1167ff5e2063b23afddd23dd8a0199f1b
First added on: Feb 07, 2025